We feel Skyepharma’s share price performance yesterday was unjustified given the recent strong news flow and future prospects. Skyepharma continues to make excellent progress in multiple areas of the business. The recent recognition of a €10m flutiform® sales milestone highlights the continued strong sales growth of the product whilst work continues in parallel to add additional indications and geographies. The development products SKP-2075 (asthma COPD crossover syndrome) and SKP-2076 (asthma t ....
09 Feb 2016
Very attractive opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Very attractive opportunity
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
09 Feb 2016 -
Author:
Sheena Berry -
Pages:
3
We feel Skyepharma’s share price performance yesterday was unjustified given the recent strong news flow and future prospects. Skyepharma continues to make excellent progress in multiple areas of the business. The recent recognition of a €10m flutiform® sales milestone highlights the continued strong sales growth of the product whilst work continues in parallel to add additional indications and geographies. The development products SKP-2075 (asthma COPD crossover syndrome) and SKP-2076 (asthma t ....